Progress in Chromovitrectomy

Guest Editor:
Carsten H. Meyer, Aarau
Chromovitrectomy is a novel approach to visualize the vitreous or retinal surface during vitreoretinal surgery. In recent years, the widely used indocyanine green (ICG) has made the surgical maneuver of inner limiting membrane peeling tremendously safer and efficient. Also, numerous dyes have been applied in experimental settings with promising or devastating results. This volume highlights the major clinical and experimental results of currently used novel vital dyes. The first chapters describe the transparent structure of the vitreous body and summarize historical considerations to visualize its structure by optical coherence tomography, dye injections or autologous cells during surgery and for diagnostic purposes. The following contributions describe the advantages and disadvantages of ICG during vitreoretinal surgery and experimental applications. Alternative approaches by recently approved vital dyes such as trypan blue, patent blue and brilliant blue are evaluated in the subsequent chapters. Finally, the last few chapters give an outlook on novel vital dyes, which are currently under evaluation, as well as alternative enzymatic approaches to remove the vitreous from the retinal surface.

Being a timely update this publication will be indispensable reading for vitreoretinal surgeons and ophthalmic researchers.
Submission

Original papers, reviews and carefully selected case reports written in English are considered for publication. Manuscripts should be submitted online at www.karger.com/oph

Should you experience any problems with your submission, please contact the Editorial Office at:
oph@karger.com

Prof. J. Caruza-Vaz
S. Karger AG
Editorial Office ‘Ophthalmologica’
PO Box
CH-4009 Basel (Switzerland)
Fax +41 61 306 1434

Conditions

All manuscripts are subject to editorial review. Manuscripts are received with the explicit understanding that they are not under simultaneous consideration by any other publication. A cover letter with the name, address, and telephone and telefax numbers of the corresponding author must accompany each manuscript. This letter must include a statement that affirms that all authors concur with the submission. Submission of an article for publication implies transfer of the copyright from the author to the publisher upon acceptance. Accepted papers become the permanent property of ‘Ophthalmologica’ and may not be reproduced by any means, in whole or in part, without the written consent of the publisher. It is the author’s responsibility to obtain permission to reproduce illustrations, tables, etc. from other publications.

Conflicts of Interest

Authors are required to disclose any sponsorship or funding arrangements relating to their research and all authors should disclose any possible conflicts of interest. Conflict of interest statements will be published at the end of the article.

Types of Papers

Editorial
EURETINA – Review
EURETINA – Original Paper
Original Paper
Review
New Technologies in Ophthalmology
Letter to the Editor

Reviews are either invited, or may be submitted for consideration. Invited reviews, if accepted, are not subject to page charges. The recommended length is 6 printed pages (approx. 15 double-spaced manuscript pages).

Mini Reviews should contain an easy-to-read literature overview on a specific topic. Papers are either invited or may be submitted for consideration. Only concise articles of no more than 2 printed pages (approx. 6 double-spaced manuscript pages), including an abstract of max. 200 words and references, will be accepted. Please submit your mini review online.

Letter to the Editor

Letters are only accepted if they directly concern articles previously published in this journal and clinical subjects related to the matters discussed. The editor reserves the right to submit copies of such letters to the authors of the articles concerned prior to publication in order to permit them to respond in the same issue of the journal. Letters should have a maximum of one printed page (350–420 words, up to 8 references).

Arrangement

Title page: The first page of each paper should indicate the title, the authors’ names, the institute where the work was conducted, and a short title for use as running head.

Full address: The exact postal address of the corresponding author complete with postal code must be given at the bottom of the title page. Please also supply phone and fax numbers, as well as e-mail address.

Key words: Please supply 3–10 key words in English that reflect the content of the paper.

Abstract: Each paper needs an abstract in English of not more than 150 words. The abstract is of utmost importance. It should contain the following information: purpose of the study, procedures, results, conclusions and message of the paper.

Footnotes: Avoid footnotes.

Tables and illustrations: Tables and illustrations (both numbered in Arabic numerals) should be sent in separate files. Tables require a heading and figures a legend, also in a separate file. Due to technical reasons, figures with a screen background should not be submitted. When possible, group several illustrations in one block for reproduction (max. size 180 × 223 mm). Black and white half-tone and color illustrations must have a final resolution of 300 dpi after scaling, line drawings one of 800–1,200 dpi.

Color illustrations

Online edition: Color illustrations are reproduced free of charge. In the print version, the illustrations are reproduced in black and white. Please avoid referring to the colors in the text and figure legends.

Print edition: Up to 6 color illustrations per page can be integrated within the text at CHF 800.– per page.

References: In the text identify references by Arabic numerals [in square brackets]. Material submitted for publication but not yet accepted should be noted as ‘unpublished data’ and not be included in the reference list. The list of references should include only those publications which are cited in the text. Do not alphabetize; number references in the order in which they are first mentioned in the text. The surname(s) of the authors followed by initials should be given. There should be no punctuation other than a comma to separate the authors. Preferably, please cite all authors. Abbreviate journal names according to the Index Medicus system. Also see International Committee of Medical Journal Editors Uniform requirements for manuscripts submitted to biomedical journals (www.icmje.org).

Examples


(b) Papers published only with DOI numbers: Theoharis TC, Boucher W, Spear K: Serum interleukin-6 reflects disease severity and osteoporosis in mastocytosis patients. Int Arch Allergy Immunol 10.1159/000063588.


Reference Management Software: Use of EndNote is recommended for easy management and formatting of citations and reference lists.

Digital Object Identifier (DOI)

S. Karger Publishers supports DOIs as unique identifiers for articles. A DOI number will be printed on the title page of each article. DOIs can be useful in the future for identifying and citing articles published online without volume or issue information. More information can be found at www.doi.org.

Supplementary Material

Supplementary material is restricted to additional data that are not necessary for the scientific integrity and conclusions of the paper. Please note that all supplementary files will undergo editorial review and should be submitted together with the original manuscript. The Editors reserve the right to limit the scope and length of the supplementary material. Supplementary material must meet production quality standards for Web publication without the need for any modification or editing. In general, supplementary files should not exceed 10 MB in size. All figures and tables should have titles and legends and all files should be supplied separately and named clearly. Acceptable files and formats are: Word or PDF files, Excel spreadsheets (only if the data cannot be converted properly to a PDF file), and video files (.mov, .avi, .mpeg).

Author’s Choice

Karger’s Author’s Choice service broadens the reach of your article and gives all users worldwide free and full access for reading, downloading and printing at www.karger.com. The option is available for a one-time fee of CHF 3000.–, which is a permissible cost in grant allocation. More information can be found at www.karger.com/author’s_choice.

NIH-Funded Research

The U.S. National Institutes of Health (NIH) mandates under the NIH Public Access Policy that final, peer-reviewed manuscripts appear in its digital database within 12 months of the official publication date. As a service to authors, Karger submits the final version of your article on your behalf to PubMed Central. For those selecting our premium Author’s Choice service, we will send your article immediately upon publishing, accelerating the accessibility of your work without the usual embargo. More details on NIH’s Public Access Policy are available at http://publicaccess.nih.gov/policy.htm.

Self-Archiving

Karger permits authors to archive their pre-prints (i.e. pre-refereeing) or post-prints (i.e. final draft post-refereeing) on their personal or institution’s servers, provided the following conditions are met: Articles may not be used for commercial purposes, must be linked to the publisher’s version, and must acknowledge the publisher’s copyright. Authors selecting Karger’s Author’s Choice feature, however, are also permitted to archive the final, published version of their article, which includes copyediting and design improvements as well as citation links.

Page Charges

There are no page charges for papers of 3 or fewer printed pages (including tables, illustrations and references). Each additional complete or partial page is charged to the author at CHF 325.–. The allotted size of a paper is equal to approx. 8 manuscript pages (including tables, illustrations and references).

Proofs

Unless indicated otherwise, proofs are sent to the corresponding author and should be returned with the least possible delay. Alterations other than the correction of printer’s errors are charged to the author.

Reprints

Order forms and a price list are sent with the proofs. Orders submitted after the issue is printed are subject to considerably higher prices.

KARGER © 2013 S. Karger AG, Basel
E-Mail karger@karger.com
www.karger.com

The Guidelines for Authors are available at:
www.karger.com/oph_Guidelines

Guidelines for Authors
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publisher or the editor(s). The appearance of advertisements in this publication does not constitute a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Subscription Rates: Subscriptions run for a full calendar year. Prices are given per year.

- Personal subscription:
  - Print or Online: CHF 1018.– / EUR 820.– / USD 1008.00
  - Postage and handling: CHF 57.60 Europe, CHF 83.20 Overseas
  - Institutional subscription:
    - Print or Online: CHF 2034.– / EUR 1640.– / USD 2014.00
    - Postage and handling: CHF 72.– Europe, CHF 104.– Overseas

Discount subscription prices:
- Association for Research and Vision in Ophthalmology (ARVO)
- EURO
- EURETINA
- and other related societies

Back Volumes and Single Issues: Information on availability and prices of single print issues and print or electronic back volumes can be obtained from Customer Service at service@karger.com.

Bibliographic Indices: This journal is regularly listed in bibliographic services, including Current Contents® and PubMed/MEDLINE.

Photocopying: This journal has been registered with the Copyright Clearance Center (CCC), as indicated by the code appearing on the first page of each article. For readers in the US, this code signals consent for copying of articles for personal or internal use, or for personal or internal use of specific clients, provided that the stated fee is paid per copy directly to Copyright Clearance Center Inc. 222 Rosewood Drive Danvers, MA 01923 (USA)

A copy of the first page of the article must accompany payment. Consent does not extend to copying for general distribution, for promotion, for creating new works, or for resale. In these cases, specific written permission must be obtained from the copyright owner, S. Karger AG, P.O. Box CH–4009 Basel (Switzerland).

Photocopying by non-profit organizations for educational use is accepted without restriction.
New Treatments in Noninfectious Uveitis

Editors
Elisabetta Miserocchi
Giulio Modorati
C. Stephen Foster

Uveitis is a potentially blinding inflammatory disease that presents one of the most serious and complicated therapeutic challenges in the field of ophthalmology. During the last decade, the therapeutic armamentarium of the uveitis specialist has enormously expanded. Novel biologic agents and intraocular therapy are becoming a valuable alternative treatment to control ocular inflammatory diseases and inflammatory macular edema – the most important cause of visual loss in patients with uveitis.

This publication is designed to bring together the principles of therapy of patients with non-infectious uveitis and the most recent therapeutic options available. General ophthalmologists, uveitis specialists as well as residents will find it a useful update on the latest innovative treatment options for patients with non-infectious uveitis.

Contents

Preface: Miserocchi, E.; Modorati, G.; Foster, C.S.
The Philosophy of Treatment of Uveitis: Past, Present and Future: Kruh, J.; Foster, C.S.
The Gold Standard of Noninfectious Uveitis: Corticosteroids: Lehoang, P.
Corticosteroid-Sparing Agents: Conventional Systemic Immunosuppressants: Kruh, J.; Foster, C.S.
Mycophenolate Mofetil Use in the Treatment of Noninfectious Uveitis: Kilsovic, D.D.
Anti-Tumor Necrosis Factor-α Agents in Noninfectious Uveitis: Gueudry, J.; LeHoang, P.; Badagli, B.
New Biologic Drugs: Anti-Interleukin Therapy: Tappeiner, C.; Müller, B.; Hennig, M.; Heiligenhaus, A.
Interferon-α Therapy in Noninfectious Uveitis: Deuter, C.; Stübiger, N.; Zierhut, M.
Rituximab for Noninfectious Uveitis: Miserocchi, E.; Modorati, G.
Intravitreal Injection Therapy in the Treatment of Noninfectious Uveitis: Modorati, G.; Miserocchi, E.
Corticosteroid Intravitreal Implants: de Smet, M.D.

Subject Index
Contents

See the journal website for contents
A comprehensive and in-depth review
by leading experts

Medical Retina

Editors
Francesco Bandello
Giuseppe Querques

Contents

Foreword: Guarnaccia, G.
Preface: Bandello, F.; Querques, G.

Embryology and Anatomy of the Baby’s Posterior Segment: Trese, M.T.
Blood-Retinal Barrier and Its Relevance in Retinal Disease: Cunha-Vaz, J.
Imaging the Retina: Cunha-Vaz, J.
Do We Need Fluorescein Angiography? Noninvasive Imaging of the Eye Fundus: Cunha-Vaz, J.

Treatment of Retinopathy of Prematurity: Capone, A., Jr.
Retinal Development and the Pathogenesis of Retinopathy of Prematurity: Capone, A., Jr.
Retinopathy of Prematurity: Cases and Diagnosis: Trese, M.T.
Retinopathy of Prematurity: Laser Treatment and Intravitreal Injections: Trese, M.T.

Vitreoretinal Surgery for Retinopathy of Prematurity: Trese, M.T.
Proliferative Vitreoretinopathy: Mateo, C.; Burés-Jelstrup, A.
Inherited Retinal Pigmentary Degenerations and Inherited Macular Dystrophies: Navarro, R.; Burés-Jelstrup, A.

Pediatric Vitreoretinal Diseases Not Associated with Prematurity: Capone, A., Jr.

Other Vitreoretinal Pathologies in Infants:
Trese, M.T.

Vascular Anomalies of the Fundus Oculi: Diagnosis and Treatment: Lanzetta, P.; Veritti, D.
Retinal Artery Occlusion: Bandello, F.; Battaglia Parodi, M.
Retinal Artery Occlusion and Acute Choroidal Ischemia: Gaudric, A.
Ocular Ischemic Syndrome: Capone, A., Jr.

Retinal Artery Occlusion and Acute Choroidal Ischemia: Gaudric, A.
Retinal Venous Occlusion: Garcia-Arumi, J.; Badal, J.; Zapata, M.; Boixadera, A.; Martinez-Castillo, V.
Fine-Needle Aspiration Biopsy in Intraocular Tumors: Pelayes, D.E.

Myopic Macula: Mateo, C.; Burés-Jelstrup, A.
Pathogenesis of Age-Related Macular Degeneration: Zarbin, M.A.
Diabetic Retinopathy: Williams, G.A.
Diabetic Macular Edema: Williams, G.A.
Diabetic Macular Edema: Williams, G.A.

Diabetic Retinopathy: Surgery: Garcia-Arumi, J.; Badal, J.; Zapata, M.; Boixadera, A.; Martinez-Castillo, V.
 Vitrectomy for Macular Hole: Gaudric, A.; Tadayoni, R.

Pathogenesis of Age-Related Macular Degeneration: Zarbin, M.A.
Treatment of Dry Age-Related Macular Degeneration: Zarbin, M.A.; Rosenfeld, P.J.
Intraocular Tumors: Pelayes, D.E.

Subject Index
An update on the essentials of retina surgery

Surgical Retina

Editors
Francesco Bandello
Maurizio Battaglia Parodi

Contents

Preface: Bandello, F.; Battaglia Parodi, M.

Diabetic Retinopathy Management: Zarbin, M.A.; Smiddy, W.E.

Nonsurgical Options for the Treatment of Diabetic Macular Edema: Pournaras, C.J.; Mendarinos, E.; Pournaras, J.-A.

Use of Anti-Vascular Endothelial Growth Factor Drugs for Diabetic Macular Edema: Falcomatà, B.; Battaglia Parodi, M.; Iacono, P.; Guaraccia, G.; Bandello, F.

Proliferative Diabetic Retinopathy: Laser Treatment and Intravitreal Medication: Bandello, F.; Battaglia Parodi, M.; Lattanzio, R.; Knutsson, A.

Proliferative Diabetic Retinopathy: Surgical Treatment: Kampik, A.

Complications and Management of Diabetic Vitrectomy: Zarbin, M.A.

Diabetic Macular Edema: Cases and Diagnostics: Pournaras, C.J.; Pournaras, J.-A.; Mendarinos, E.

Retinal Venous Occlusions: Diagnosis and Choice of Treatments: García-Arumí, J.; Badal, J.; Zapata, M.; Boixadera, A.; Martínez Castillo, V.

Rhegmatogenous Retinal Detachment: Clinical Preoperative and Postoperative Handling: Fischer, N.; Loewenstein, A.

Making Sense of Prophylaxis for Retinal Detachment: Ayward, G.W.

Ab externo Surgery of Rhegmatogenous Retinal Detachment: Handling of Intraoperative and Postoperative Complications: Klein, A.; Loewenstein, A.

Vitrectomy for Rhegmatogenous Retinal Detachment: Ayward, G.W.

Scleral Buckling Materials: Rizzo, S.; Genovesi-Ebert, F.; Allegri, L.

Pneumatic Retinopexy: Rizzo, S.; Genovesi-Ebert, F.; Allegri, L.

Retinal Detachment by Giant Tear or Dialysis: Moisseiev, E.; Loewenstein, A.

Macular Hole Surgery: García-Arumí, J.; Badía, C.M.

Vitrectomy for Epiretinal Membrane: Gaudric, A.; Tadayoni, R.

Irvine-Gass Syndrome: Kampik, A.

Endophthalmitis: Zarbin, M.A.

Subject Index
Patient-oriented scientific reports covering all aspects of ophthalmology

Ophthalmologica

The Journal of the European Society of Retina Specialists

Editor
J. Cunha-Vaz, Coimbra

Associate Editors
J. Bainbridge, London
F. Bandello, Milan
F. Behar-Cohen, Paris
R. Belfort Jr., São Paulo
G. Coscas, Créteil
J.C.N. Murta, Coimbra
Y. Ogura, Nagoya
R.J. Olson, Salt Lake City
N. Pfeiffer, Mainz
G. Richard, Hamburg
S. Wolf, Bern

Selected contributions
- Management of Retinal Vein Occlusion—Consensus Document: Coscas, G. (Créteil); Loewenstein, A. (Tel Aviv); Augustin, A. (Karlsruhe); Bandello, F.; Battaglia Parodi, M. (Milan); Lanzetta, P. (Udine); Monés, J. (Barcelona); de Smet, M. (Amsterdam); Soubrane, G. (Créteil); Staurenghi, G. (Milan)
- Müller Glial Cells in Retinal Disease: Bringmann, A.; Wiedemann, P. (Leipzig)
- Oxygen Sensing in Retinal Health and Disease: Lange, C.A.K. (London/Freiburg); Bainbridge, J.W.B. (London)
- Noninvasive Evaluation of Retinal Leakage Using Optical Coherence Tomography: Bernards, R.; Santos, T.; Serramo, P.; Lobo, C.; Cunha-Vaz, J. (Coimbra)
- Imaging Geographic Atrophy in Age-Related Macular Degeneration: Göbel, A.P.; Fleckenstein, M.; Schmitz-Valckenberg, S.; Brinkmann, C.K.; Holz, F.G. (Bonn)
- Outcomes of Epiretinal Membrane Removal in Eyes with and without Concurrent Vision-Limiting Ocular Disease: Moisseiev, E.; Davidovitch, Z.; Loewenstein, A.; Barak, A. (Tel Aviv)
- Improved Automated Screening of Diabetic Retinopathy: Oliveira, C.M.; Cristovão, L.M.; Ribeiro, M.L.; Faria Abreu, J.R. (Coimbra)

Published since 1899, Ophthalmologica has become a frequently cited guide to international work in clinical and experimental ophthalmology. It contains a selection of patient-oriented contributions covering the etiology of eye diseases, diagnostic techniques, and advances in medical and surgical treatment, with special emphasis on retinal diseases. In addition to original papers, Ophthalmologica features regularly timely reviews in an effort to keep the reader well informed and updated. The large international circulation of this journal reflects its importance.
1 Editorial

3 Chromovitrectomy and the Vitreoretinal Interface
Schumann, R.G.; Haritoglou, C. (Munich)

11 Material Properties of the Internal Limiting Membrane and Their Significance in Chromovitrectomy
Henrich, P.B.; Monnier, C.A.; Loparic, M.; Cattin, P.C. (Basel)

21 The Retinal Biocompatibility of Dyes in the ex vivo Model of the Isolated Superfused Vertebrate Retina
Lüke, M.; Grisanti, S.; Lüke, J. (Lübeck)

27 Improved Brilliant Blue G Staining of the Internal Limiting Membrane with Sharp Cut Filters of a Novel Viewing Filter System
Enaida, H.; Yoshida, S.; Nakao, S.; Ikeda, Y. (Fukuoka); Hachisuka, Y.; Oshima, Y. (Tokyo); Kadonosono, K. (Yokohama); Ueno, A.; Ishibashit, T. (Fukuoka)

33 Effect of Novel Vital Dyes on Outer Blood-Retina Barrier Function in Cultured Human Retinal Pigment Epithelium
Liu, Z. (Bonn); Meyer, C.H. (Bonn/Olten); Stanzel, B.V. (Bonn)

41 Effect of Vital Dyes on Retinal Pigmented Epithelial Cell Viability and Apoptosis: Implications for Chromovitrectomy
Penha, F.M. (São Paulo); Pons, M. (Miami, Fla.); de Paula Fiod Costa, E.; Rodrigues, E.B.; Maia, M. (São Paulo); Marin-Castañó, M.E. (Miami, Fla.); Farah, M.E. (São Paulo)

51 Dyes for Eyes™: Hydrodynamics, Biocompatibility and Efficacy of ‘Heavy’ (Dual) Dyes for Chromovitrectomy
Mohr, A. (Bremen); Bruinsma, M.; Oellerich, S. (Rotterdam); Frank, H. (Delft); Gabel, D. (Bremen); Melles, G.R.J. (Rotterdam)

59 Biochemical Analysis and Decomposition Products of Indocyanine Green in Relation to Solvents, Dye Concentrations and Laser Exposure

68 Staining Properties of Brilliant Blue Depending on Different Incubation Times and Solvents in Humans

73 A Trichrome RGB Endoillumination Prototype System: A Novel Application for Chromovitrectomy

77 Author Index/Subject Index

Cover illustration
Permission to use this illustration was kindly granted by Andreas Knauf.